ReShape Lifesciences Announces Attendance and Presentation at ObesityWeek 2018

SAN CLEMENTE, CA / ACCESSWIRE / October 25, 2018 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the Company will be exhibiting its products and will be the subject of a poster presentation at ObesityWeek 2018, taking place at Music City Center in Nashville, Tennesee from November 11-15, 2018.

In addition to the ReShape Lifesciences™ 20' x 20' booth (#913), which will feature the Company's products in the Exhibit Hall, ReShape Lifesciences™ will be showcasing its proprietary ReShape vBlocTM-based combination stimulation / blocking technology, which is designed to help control glucose in patients with type 2 diabetes.

Details of the presentation:
Date: Thursday, November 15, 2018; 12:00PM – 1:30PM
Location: Music City Center; Exhibit Hall B-D, T-P-LB-3682
Presentation Title: "Dual Vagus Neuromodulation Improves Glycemic Control in Obese Rat and Pig Models of Type 2 Diabetes"
Presenter: Charles Billington, MD, Chief, Section of Endocrinology and Metabolism, Minneapolis VA Health Care System; Professor of Medicine, University of Minnesota

About ObestityWeek

ObesityWeek is the largest obesity-centric conference in the world with the broadest, most comprehensive bench-to-bedside and continuum of care content. The event brings together experts and professionals with an interest in adult and childhood obesity representing experienced Metabolic and Bariatric Surgeons, Physicians, Dietitians, Researchers, and other industry professionals. Over 4,000 obesity professionals are expected to attend ObesityWeek 2018.

For more details on ObesityWeek 2018, please visit https://obesityweek.com.

About ReShape Lifesciences Inc.

ReShape Lifesciences™ is a medical device company focused on technologies to treat obesity and metabolic diseases. The FDA-approved ReShape Balloon™ System involves a non-surgical weight loss procedure that uses advanced balloon technology designed to take up room in the stomach to help people with a 30-40 kg/m2 Body Mass Index (BMI) and at least one co-morbidity lose weight. The ReShape Vest™ System is an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery, and is intended to enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy.

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," other words of similar meaning and the use of future dates. These forward-looking statements are based on the current expectations of our management and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others: risks and uncertainties related to our acquisitions of ReShape Medical, Inc. and BarioSurg, Inc.; risks related to the U.S. Food and Drug Administration's announcement, including updates thereto, to alert health care providers of unanticipated deaths involving the ReShape Balloon; our proposed ReShape Vest product may not be successfully developed and commercialized; our ability to continue as a going concern if we are unsuccessful in our pursuit of various funding options; our limited history of operations; our losses since inception and for the foreseeable future; our limited commercial sales experience; the competitive industry in which we operate; our ability to maintain compliance with the Nasdaq continued listing requirements and remain listed on Nasdaq; our dependence on third parties to initiate and perform our clinical trials; the need to obtain regulatory approval for our ReShape Vest and any modifications to our vBloc system or ReShape Balloon; physician adoption of our products; our ability to obtain third party coding, coverage or payment levels; ongoing regulatory compliance; our dependence on third party manufacturers and suppliers; the successful development of our sales and marketing capabilities; our ability to raise additional capital when needed; international commercialization and operation; our ability to attract and retain management and other personnel and to manage our growth effectively; potential product liability claims; the cost and management time of operating a public company; potential healthcare fraud and abuse claims; healthcare legislative reform; and our ability to obtain and maintain intellectual property protection for our technology and products. These and additional risks and uncertainties are described more fully in the Company's filings with the Securities and Exchange Commission, particularly those factors identified as "risk factors" in our annual report on Form 10-K filed April 2, 2018 and quarterly report on Form 10-Q filed August 20, 2018. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.

Investor Contact:

SOURCE: ReShape Lifesciences Inc.